B-cell count and survival: Differentiating chronic lymphocytic leukemia from monoclonal B-cell lymphocytosis based on clinical outcome

Blood

Volumn 113, Issue 18, 2009, Pages 4188-4196

  Shanafelt, Tait D ^a   Kay, Neil E ^a   Jenkins, Greg ^a   Call, Timothy G ^a   Zent, Clive S ^a   Jelinek, Diane F ^a   Morice, William G ^a   Boysen, Justin ^a   Zakko, Liam ^a   Schwager, Susan ^a   Slager, Susan L ^a   Hanson, Curtis A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD38 ANTIGEN; IMMUNOGLOBULIN; PROTEIN IGHV; PROTEIN KINASE ZAP 70; UNCLASSIFIED DRUG; IMMUNOGLOBULIN HEAVY CHAIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CANCER SURVIVAL; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DISEASE MARKER; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; LYMPHOCYTE COUNT; LYMPHOCYTOSIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; CANCER STAGING; DIFFERENTIAL DIAGNOSIS; FLOW CYTOMETRY; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; TREATMENT OUTCOME;

AGED; B-LYMPHOCYTES; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTE COUNT; LYMPHOCYTOSIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 66149099258     PISSN: 00064971     EISSN: 15280020     Source Type: None    
DOI: 10.1182/blood-2008-09-176149     Document Type: Article

References (40)

1. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006;107:265-276.
2. Cheson BD, Bennett JM, Rai KR, et al. Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working group. Am J Hematol. 1988;29:152-163.
3. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87:4990-4997. (Pubitemid 26189840)
4. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111: 5446-5456.
5. Galton DA. The pathogenesis of chronic lymphocytic leukemia. Can Med Assoc J. 1966;94:1005-1010.
6. Committee of the Chronic Leukemia-Myeloma Task Force NCI. Proposed Guidelines for Protocol Studies. III Chronic Lymphocytic Leukemia. Cancer Chemother. 1973:159-165.
7. Silver RT, Sawitsky A, Rai K, Holland JF, Glidewell O. Guidelines for protocol studies in chronic lymphocytic leukemia. Am J Hematol. 1978;4:343-358. (Pubitemid 9066769)
8. Proposed guidelines for protocol studies. I. Introduction. II. Plasma cell myeloma. 3. Chronic lymphocytic leukemia. IV. Chronic granulocytic leukemia. Cancer Chemother Rep 3. 1973;4:141-173.
9. Chronic lymphocytic leukemia: recommendations for diagnosis, staging, and response criteria. International Workshop on Chronic Lymphocytic Leukemia. Ann Intern Med. 1989;110:236-238.
10. Call T, Phyilky R, Noel P, et al. Incidence of chronic lymphocytic leukemia in Olmsted County, Minnesota, 1935 through 1989, with emphasis on changes in initial stage at diagnosis. Mayo Clin Proc. 1994;69:323-328.
11. Rozman C, Bosch F, Montserrat E. Chronic lymphocytic leukemia: a changing natural history? Leukemia. 1997;11:775-778.
12. Molica S, Levato D. What is changing in the natural history of chronic lymphocytic leukemia. Haematologica. 2001;86:8-12. (Pubitemid 32147043)
13. Cavotsky D, Fooks J, Richards S. Prognostic factors in chronic lymphocytic leukaemia: the importance of age, sex and response to treatment in survival. Br J Haematol. 1989;72:141-149.
14. Rawstron A, Green M, Kuzmicki A, et al. Monoclonal B lymphocytes with the characteristics of "indolent" chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts. Blood. 2002;100:635-639.
15. Marti GE, Rawstron AC, Ghia P, et al. Diagnostic criteria for monoclonal B-cell lymphocytosis. Br J Haematol. 2005;130:325-332. (Pubitemid 43899581)
16. Rawstron AC, Bennett FL, O'Connor SJ, et al. Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N Engl J Med. 2008;359: 575-583.
17. Zent CS, Kyasa MJ, Evans R, Schichman SA. Chronic lymphocytic leukemia incidence is substantially higher than estimated from tumor registry data. Cancer. 2001;92:1325-1330.
18. Thurmes P, Call T, Slager S, et al. Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2008;49:49-56. (Pubitemid 351146882)
19. Shanafelt TD, Kay NE, Call TG, et al. MBL or CLL: which classification best categorizes the clinical course of patients with an absolute lymphocyte count > or = 5 x 10(9) L(-1) but a B-cell lymphocyte count < 5 x 10(9) L(-1)? Leuk Res. 2008;32:1458-1461.
20. Shanafelt TD, Bowen D, Venkat C, et al. Quality of life in chronic lymphocytic leukemia: an international survey of 1482 patients. Br J Haematol. 2007;139:255-264. (Pubitemid 47493093)
21. Victor Hoffbrand A, Hamblin TJ. Is "leukemia" an appropriate label for all patients who meet the diagnostic criteria of chronic lymphocytic leukemia? Leuk Res. 2007;31:273-275.
22. Shanafelt TD, Jelinek D, Tschumper R, et al. Cytogenetic abnormalities can change during the course of the disease process in chronic lymphocytic leukemia. J Clin Oncol. 2006;24:3218-3219. (Pubitemid 46638967)
23. Zent CS, Ding W, Schwager SM, et al. The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma. Br J Haematol. 2008;141:615-621. (Pubitemid 351667621)
24. Maddocks-Christianson K, Slager SL, Zent CS, et al. Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia. Br J Haematol. 2007;139:398-404. (Pubitemid 47512176)
25. Bowen DA, Call TG, Jenkins GD, et al. Methylprednisolone- rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features. Leuk Lymphoma. 2007;48:2412-2417.
26. Palmer S, Hanson CA, Zent CS, et al. Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia. Br J Haematol. 2008;141: 607-614. (Pubitemid 351667615)
27. Dewald G, Brockman S, Paternoster S, et al. Chromosome anomalies detected by interphase fluorescence in hybridization: correlation with significant biological features of chronic lymphocytic leukemia. Br J Haematol. 2003;121:287-295. (Pubitemid 36560596)
28. Jelinek DF, Tschumper RC, Geyer SM, et al. Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia. Br J Haematol. 2001;115:854-861.
29. Shanafelt TD, Witzig TE, Fink SR, et al. Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated earlystage chronic lymphocytic leukemia. J Clin Oncol. 2006;24:4634-4641.
30. Morice WG, Kurtin PJ, Hodnefield JM, et al. Predictive value of blood and bone marrow flow cytometry in B-cell lymphoma classification: comparative analysis of flow cytometry and tissue biopsy in 252 patients. Mayo Clin Proc. 2008;83:776-785.
31. Contal C, O'Quigley J. An application of changepoint methods in studying the effect of age on survival in breast cancer. Comput Stat Data Anal. 1999;30:253-270.
32. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15: 361-387.
33. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94:1848-1854. (Pubitemid 29430400)
34. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94:1840-1847. (Pubitemid 29430399)
35. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343: 1910-1916. (Pubitemid 32064784)
36. Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable- region mutations in chronic lymphocytic leukemia. N Engl J Med. 2003;348:1764-1775. (Pubitemid 36514707)
37. Rassenti LZ, Huynh L, Toy TL, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med. 2004;351:893-901. (Pubitemid 39096916)
38. Rassenti LZ, Jain S, Keating MJ, et al. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood. 2008;112: 1923-1930.
39. Hamblin TJ, Gardiner AC, Mould SJ, et al. Can we predict which patients with early stage CLL will progress and require treatment. Leuk Lymphoma. 2005;46:S46-P24.
40. Hanson CA, Kurtin PJ, Dogan A. The proposed diagnostic criteria change for chronic lymphocytic leukemia: unintended consequences? Blood. In press.